{"product_id":"antibacterial-agents-9780470972441","title":"Antibacterial Agents","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAntibacterial agents act against bacterial infection either by killing the bacterium or by arresting its growth. They do this by targeting bacterial DNA and its associated processes, attacking bacterial metabolic processes including protein synthesis, or interfering with bacterial cell wall synthesis and function.\u003cbr\u003e \u003cbr\u003e \u003ci\u003eAntibacterial Agents\u003c\/i\u003e is an essential guide to this important class of chemotherapeutic drugs. Compounds are organised according to their target, which helps the reader understand the mechanism of action of these drugs and how resistance can arise. The book uses an integrated lab-to-clinic approach which covers drug discovery, source or synthesis, mode of action, mechanisms of resistance, clinical aspects (including links to current guidelines, significant drug interactions, cautions and contraindications), prodrugs and future improvements.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eAgents covered include:\u003c\/b\u003e  \u003cul\u003e \u003cli\u003eagents targeting DNA - quinolone, rifamycin, and nitroimidazole \u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface xi  \u003cp\u003eSECTION 1 INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL\u003c\/p\u003e \u003cp\u003eCHEMOTHERAPY 1\u003c\/p\u003e \u003cp\u003e1.1 Microorganisms 3\u003c\/p\u003e \u003cp\u003eKey points 3\u003c\/p\u003e \u003cp\u003e1.1.1 Classification 3\u003c\/p\u003e \u003cp\u003e1.1.2 Structure 4\u003c\/p\u003e \u003cp\u003e1.1.3 Bacterial detection and identification 17\u003c\/p\u003e \u003cp\u003e1.1.4 Other than its mode of action, what factors determine the antibacterial activity of a drug? 25\u003c\/p\u003e \u003cp\u003e1.1.5 Bacterial resistance 27\u003c\/p\u003e \u003cp\u003e1.1.6 The ‘post-antibiotic age’? 29\u003c\/p\u003e \u003cp\u003eReferences 31\u003c\/p\u003e \u003cp\u003eQuestions 33\u003c\/p\u003e \u003cp\u003eSECTION 2 AGENTS TARGETING DNA 35\u003c\/p\u003e \u003cp\u003e2.1 Quinolone antibacterial agents 37\u003c\/p\u003e \u003cp\u003eKey points 37\u003c\/p\u003e \u003cp\u003e2.1.1 Discovery 37\u003c\/p\u003e \u003cp\u003e2.1.2 Synthesis 39\u003c\/p\u003e \u003cp\u003e2.1.3 Bioavailability 41\u003c\/p\u003e \u003cp\u003e2.1.4 Mode of action and selectivity 44\u003c\/p\u003e \u003cp\u003e2.1.5 Bacterial resistance 45\u003c\/p\u003e \u003cp\u003e2.1.6 Clinical applications 47\u003c\/p\u003e \u003cp\u003e2.1.7 Adverse drug reactions 50\u003c\/p\u003e \u003cp\u003e2.1.8 Drug interactions 55\u003c\/p\u003e \u003cp\u003e2.1.9 Recent developments 56\u003c\/p\u003e \u003cp\u003eReferences 60\u003c\/p\u003e \u003cp\u003e2.2 Rifamycin antibacterial agents 63\u003c\/p\u003e \u003cp\u003eKey points 63\u003c\/p\u003e \u003cp\u003e2.2.1 Discovery 63\u003c\/p\u003e \u003cp\u003e2.2.2 Synthesis 65\u003c\/p\u003e \u003cp\u003e2.2.3 Bioavailability 68\u003c\/p\u003e \u003cp\u003e2.2.4 Mode of action and selectivity 69\u003c\/p\u003e \u003cp\u003e2.2.5 Bacterial resistance 71\u003c\/p\u003e \u003cp\u003e2.2.6 Clinical applications 71\u003c\/p\u003e \u003cp\u003e2.2.7 Adverse drug reactions 77\u003c\/p\u003e \u003cp\u003e2.2.8 Drug interactions 78\u003c\/p\u003e \u003cp\u003e2.2.9 Recent developments 81\u003c\/p\u003e \u003cp\u003eReferences 81\u003c\/p\u003e \u003cp\u003e2.3 Nitroimidazole antibacterial agents 85\u003c\/p\u003e \u003cp\u003eKey points 85\u003c\/p\u003e \u003cp\u003e2.3.1 Discovery 85\u003c\/p\u003e \u003cp\u003e2.3.2 Synthesis 86\u003c\/p\u003e \u003cp\u003e2.3.3 Bioavailability 86\u003c\/p\u003e \u003cp\u003e2.3.4 Mode of action and selectivity 87\u003c\/p\u003e \u003cp\u003e2.3.5 Mechanisms of resistance 89\u003c\/p\u003e \u003cp\u003e2.3.6 Clinical applications 90\u003c\/p\u003e \u003cp\u003e2.3.7 Adverse drug reactions and contraindications 94\u003c\/p\u003e \u003cp\u003e2.3.8 Drug interactions 95\u003c\/p\u003e \u003cp\u003e2.3.9 Recent developments 97\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003eQuestions 101\u003c\/p\u003e \u003cp\u003eSECTION 3 AGENTS TARGETING METABOLIC PROCESSES 103\u003c\/p\u003e \u003cp\u003e3.1 Sulfonamide antibacterial agents 105\u003c\/p\u003e \u003cp\u003eKey points 105\u003c\/p\u003e \u003cp\u003e3.1.1 Discovery 105\u003c\/p\u003e \u003cp\u003e3.1.2 Synthesis 107\u003c\/p\u003e \u003cp\u003e3.1.3 Bioavailability 108\u003c\/p\u003e \u003cp\u003e3.1.4 Mode of action and selectivity 111\u003c\/p\u003e \u003cp\u003e3.1.5 Bacterial resistance 114\u003c\/p\u003e \u003cp\u003e3.1.6 Clinical applications 115\u003c\/p\u003e \u003cp\u003e3.1.7 Adverse drug reactions 119\u003c\/p\u003e \u003cp\u003e3.1.8 Drug interactions 122\u003c\/p\u003e \u003cp\u003e3.1.9 Recent developments 123\u003c\/p\u003e \u003cp\u003eReferences 124\u003c\/p\u003e \u003cp\u003e3.2 Trimethoprim 127\u003c\/p\u003e \u003cp\u003eKey points 127\u003c\/p\u003e \u003cp\u003e3.2.1 Discovery 127\u003c\/p\u003e \u003cp\u003e3.2.2 Synthesis 128\u003c\/p\u003e \u003cp\u003e3.2.3 Bioavailability 130\u003c\/p\u003e \u003cp\u003e3.2.4 Mode of action and selectivity 130\u003c\/p\u003e \u003cp\u003e3.2.5 Bacterial resistance 136\u003c\/p\u003e \u003cp\u003e3.2.6 Clinical applications 136\u003c\/p\u003e \u003cp\u003e3.2.7 Adverse drug reactions 138\u003c\/p\u003e \u003cp\u003e3.2.8 Drug interactions 138\u003c\/p\u003e \u003cp\u003e3.2.9 Recent developments 139\u003c\/p\u003e \u003cp\u003eReferences 140\u003c\/p\u003e \u003cp\u003eQuestions 145\u003c\/p\u003e \u003cp\u003eSECTION 4 AGENTS TARGETING PROTEIN SYNTHESIS 147\u003c\/p\u003e \u003cp\u003e4.1 Aminoglycoside antibiotics 149\u003c\/p\u003e \u003cp\u003eKey points 149\u003c\/p\u003e \u003cp\u003e4.1.1 Discovery 149\u003c\/p\u003e \u003cp\u003e4.1.2 Synthesis 152\u003c\/p\u003e \u003cp\u003e4.1.3 Bioavailability 156\u003c\/p\u003e \u003cp\u003e4.1.4 Mode of action and selectivity 158\u003c\/p\u003e \u003cp\u003e4.1.5 Bacterial resistance 160\u003c\/p\u003e \u003cp\u003e4.1.6 Clinical applications 161\u003c\/p\u003e \u003cp\u003e4.1.7 Adverse drug reactions 165\u003c\/p\u003e \u003cp\u003e4.1.8 Drug interactions 167\u003c\/p\u003e \u003cp\u003e4.1.9 Recent developments 168\u003c\/p\u003e \u003cp\u003eReferences 168\u003c\/p\u003e \u003cp\u003e4.2 Macrolide antibiotics 173\u003c\/p\u003e \u003cp\u003eKey points 173\u003c\/p\u003e \u003cp\u003e4.2.1 Discovery 173\u003c\/p\u003e \u003cp\u003e4.2.2 Synthesis 175\u003c\/p\u003e \u003cp\u003e4.2.3 Bioavailability 177\u003c\/p\u003e \u003cp\u003e4.2.4 Mode of action and selectivity 180\u003c\/p\u003e \u003cp\u003e4.2.5 Bacterial resistance 181\u003c\/p\u003e \u003cp\u003e4.2.6 Clinical applications 182\u003c\/p\u003e \u003cp\u003e4.2.7 Adverse drug reactions 187\u003c\/p\u003e \u003cp\u003e4.2.8 Drug interactions 189\u003c\/p\u003e \u003cp\u003e4.2.9 Recent developments 192\u003c\/p\u003e \u003cp\u003eReferences 193\u003c\/p\u003e \u003cp\u003e4.3 Tetracycline antibiotics 197\u003c\/p\u003e \u003cp\u003eKey points 197\u003c\/p\u003e \u003cp\u003e4.3.1 Discovery 197\u003c\/p\u003e \u003cp\u003e4.3.2 Synthesis 200\u003c\/p\u003e \u003cp\u003e4.3.3 Bioavailability (agwuh and macgowan, 2006) 205\u003c\/p\u003e \u003cp\u003e4.3.4 Mode of action and selectivity 210\u003c\/p\u003e \u003cp\u003e4.3.5 Bacterial resistance 213\u003c\/p\u003e \u003cp\u003e4.3.6 Clinical applications 217\u003c\/p\u003e \u003cp\u003e4.3.7 Adverse drug reactions 223\u003c\/p\u003e \u003cp\u003e4.3.8 Drug interactions 224\u003c\/p\u003e \u003cp\u003e4.3.9 Recent developments 224\u003c\/p\u003e \u003cp\u003eReferences 225\u003c\/p\u003e \u003cp\u003e4.4 Chloramphenicol 231\u003c\/p\u003e \u003cp\u003eKey points 231\u003c\/p\u003e \u003cp\u003e4.4.1 Discovery 231\u003c\/p\u003e \u003cp\u003e4.4.2 Synthesis 231\u003c\/p\u003e \u003cp\u003e4.4.3 Bioavailability 232\u003c\/p\u003e \u003cp\u003e4.4.4 Mode of action and selectivity 235\u003c\/p\u003e \u003cp\u003e4.4.5 Bacterial resistance 235\u003c\/p\u003e \u003cp\u003e4.4.6 Clinical applications 236\u003c\/p\u003e \u003cp\u003e4.4.7 Adverse drug reactions 238\u003c\/p\u003e \u003cp\u003e4.4.8 Drug interactions 239\u003c\/p\u003e \u003cp\u003e4.4.9 Recent developments 239\u003c\/p\u003e \u003cp\u003eReferences 241\u003c\/p\u003e \u003cp\u003e4.5 Oxazolidinones 243\u003c\/p\u003e \u003cp\u003eKey points 243\u003c\/p\u003e \u003cp\u003e4.5.1 Discovery 243\u003c\/p\u003e \u003cp\u003e4.5.2 Synthesis 245\u003c\/p\u003e \u003cp\u003e4.5.3 Bioavailability 247\u003c\/p\u003e \u003cp\u003e4.5.4 Mode of action and selectivity 248\u003c\/p\u003e \u003cp\u003e4.5.5 Bacterial resistance 249\u003c\/p\u003e \u003cp\u003e4.5.6 Clinical applications 251\u003c\/p\u003e \u003cp\u003e4.5.7 Adverse drug reactions 252\u003c\/p\u003e \u003cp\u003e4.5.8 Drug interactions 253\u003c\/p\u003e \u003cp\u003e4.5.9 Recent developments 254\u003c\/p\u003e \u003cp\u003eReferences 254\u003c\/p\u003e \u003cp\u003eQuestions 259\u003c\/p\u003e \u003cp\u003eSECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS 261\u003c\/p\u003e \u003cp\u003e5.1 b-lactam antibiotics 263\u003c\/p\u003e \u003cp\u003eKey points 263\u003c\/p\u003e \u003cp\u003e5.1.1 Discovery 263\u003c\/p\u003e \u003cp\u003e5.1.2 Synthesis 272\u003c\/p\u003e \u003cp\u003e5.1.3 Bioavailability 277\u003c\/p\u003e \u003cp\u003e5.1.4 Mode of action and selectivity 284\u003c\/p\u003e \u003cp\u003e5.1.5 Bacterial resistance 285\u003c\/p\u003e \u003cp\u003e5.1.6 Clinical applications 290\u003c\/p\u003e \u003cp\u003e5.1.7 Adverse drug reactions 296\u003c\/p\u003e \u003cp\u003e5.1.8 Drug interactions 298\u003c\/p\u003e \u003cp\u003e5.1.9 Recent developments 300\u003c\/p\u003e \u003cp\u003eReferences 301\u003c\/p\u003e \u003cp\u003e5.2 Glycopeptide antibiotics 305\u003c\/p\u003e \u003cp\u003e5.2.1 Discovery 305\u003c\/p\u003e \u003cp\u003e5.2.2 Synthesis 305\u003c\/p\u003e \u003cp\u003e5.2.3 Bioavailability 307\u003c\/p\u003e \u003cp\u003e5.2.4 Mode of action and selectivity 308\u003c\/p\u003e \u003cp\u003e5.2.5 Bacterial resistance 311\u003c\/p\u003e \u003cp\u003e5.2.6 Clinical applications 313\u003c\/p\u003e \u003cp\u003e5.2.7 Adverse drug reactions 314\u003c\/p\u003e \u003cp\u003e5.2.8 Drug interactions 315\u003c\/p\u003e \u003cp\u003e5.2.9 Recent developments 316\u003c\/p\u003e \u003cp\u003eReferences 317\u003c\/p\u003e \u003cp\u003e5.3 Cycloserine 319\u003c\/p\u003e \u003cp\u003eKey points 319\u003c\/p\u003e \u003cp\u003e5.3.1 Discovery 319\u003c\/p\u003e \u003cp\u003e5.3.2 Synthesis 319\u003c\/p\u003e \u003cp\u003e5.3.3 Bioavailability 320\u003c\/p\u003e \u003cp\u003e5.3.4 Mode of action and selectivity 321\u003c\/p\u003e \u003cp\u003e5.3.5 Bacterial resistance 323\u003c\/p\u003e \u003cp\u003e5.3.6 Clinical applications 323\u003c\/p\u003e \u003cp\u003e5.3.7 Adverse drug reactions and contraindications 325\u003c\/p\u003e \u003cp\u003e5.3.8 Drug interactions 325\u003c\/p\u003e \u003cp\u003e5.3.9 Recent developments 325\u003c\/p\u003e \u003cp\u003eReferences 325\u003c\/p\u003e \u003cp\u003e5.4 Isoniazid 327\u003c\/p\u003e \u003cp\u003eKey points 327\u003c\/p\u003e \u003cp\u003e5.4.1 Discovery 327\u003c\/p\u003e \u003cp\u003e5.4.2 Synthesis 328\u003c\/p\u003e \u003cp\u003e5.4.3 Bioavailability 329\u003c\/p\u003e \u003cp\u003e5.4.4 Mode of action and selectivity 329\u003c\/p\u003e \u003cp\u003e5.4.5 Bacterial resistance 330\u003c\/p\u003e \u003cp\u003e5.4.6 Clinical applications 331\u003c\/p\u003e \u003cp\u003e5.4.7 Adverse drug reactions and contraindications 333\u003c\/p\u003e \u003cp\u003e5.4.8 Drug interactions 334\u003c\/p\u003e \u003cp\u003e5.4.9 Recent developments 335\u003c\/p\u003e \u003cp\u003eReferences 335\u003c\/p\u003e \u003cp\u003e5.5 Daptomycin 339\u003c\/p\u003e \u003cp\u003eKey points 339\u003c\/p\u003e \u003cp\u003e5.5.1 Discovery 339\u003c\/p\u003e \u003cp\u003e5.5.2 Synthesis 340\u003c\/p\u003e \u003cp\u003e5.5.3 Bioavailability 341\u003c\/p\u003e \u003cp\u003e5.5.4 Mode of action and selectivity 341\u003c\/p\u003e \u003cp\u003e5.5.5 Bacterial resistance 343\u003c\/p\u003e \u003cp\u003e5.5.6 Clinical applications 343\u003c\/p\u003e \u003cp\u003e5.5.7 Adverse drug reactions and contraindications 344\u003c\/p\u003e \u003cp\u003e5.5.8 Recent developments 345\u003c\/p\u003e \u003cp\u003eReferences 346\u003c\/p\u003e \u003cp\u003eQuestions 349\u003c\/p\u003e \u003cp\u003eIndex 351\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49525398339927,"sku":"9780470972441","price":121.55,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470972441.jpg?v=1731860360","url":"https:\/\/bookcurl.com\/products\/antibacterial-agents-9780470972441","provider":"Book Curl","version":"1.0","type":"link"}